| scholarly article | Q13442814 |
| P356 | DOI | 10.3851/IMP1502 |
| P698 | PubMed publication ID | 20516561 |
| P50 | author | Grace Mccomsey | Q90899761 |
| P2093 | author name string | Todd T Brown | |
| P433 | issue | 3 | |
| P921 | main subject | efavirenz | Q422645 |
| P304 | page(s) | 425-429 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Antiviral Therapy | Q4775353 |
| P1476 | title | Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. | |
| P478 | volume | 15 |
| Q34076892 | 25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings |
| Q90368294 | A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV |
| Q64060354 | Adherence to risk management guidelines for drugs which cause vitamin D deficiency - big data from the Swedish health system |
| Q41063299 | An oral high dose of cholecalciferol restores vitamin D status in deficient postmenopausal HIV-1-infected women independently of protease inhibitors therapy: a pilot study |
| Q27011921 | Anti-Inflammatory and Antimicrobial Actions of Vitamin D in Combating TB/HIV |
| Q35859876 | Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans |
| Q40087344 | Associations of Low Vitamin D and Elevated Parathyroid Hormone Concentrations With Bone Mineral Density in Perinatally HIV-Infected Children |
| Q42203594 | Bone alterations associated with HIV. |
| Q38792298 | Bone health and HIV in resource-limited settings: a scoping review |
| Q38095828 | Bone health and human immunodeficiency virus infection |
| Q36330955 | Bone loss in HIV: a contemporary review |
| Q36154208 | Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies |
| Q35000905 | Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o |
| Q40267569 | Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s |
| Q37560008 | Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens |
| Q38131941 | Challenges in the management of osteoporosis and vitamin D deficiency in HIV infection. |
| Q40461045 | Change in serum 25-hydroxyvitamin D with antiretroviral treatment initiation and nutritional intervention in HIV-positive adults. |
| Q35154069 | Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings |
| Q38973122 | Changes in bone turnover markers with HIV seroconversion and ART initiation |
| Q39010553 | Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years |
| Q34547655 | Complications of HIV disease and antiretroviral treatment. |
| Q40146615 | Counter-intuitive plasma vitamin D and zinc status in HIV-1-infected adults with persistent low-level viraemia after treatment initiation: a pilot case-control study. |
| Q36736469 | Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. |
| Q34570942 | Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach |
| Q42230910 | Different strategies of 25OH vitamin D supplementation in HIV-positive subjects |
| Q34786514 | Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study |
| Q41644519 | Effect of a monthly dose of calcidiol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients |
| Q38776710 | Effects of Osteoporosis-Inducing Drugs on Vitamin D-Related Gene Transcription and Mineralization in MG-63 and Saos-2 Cells |
| Q38978858 | Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth |
| Q33880418 | Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial |
| Q35024409 | Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study |
| Q37787098 | HIV and Bone Loss |
| Q36381079 | HIV and its effects on bone: a primer for rheumatologists |
| Q30249771 | HIV infection and bone disease |
| Q38055705 | HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options. |
| Q46543775 | Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy |
| Q93142174 | Human Immunodeficiency Virus Infection and the Endocrine System |
| Q26740117 | Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions |
| Q36177899 | Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. |
| Q37016495 | In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. |
| Q33828335 | LL-37 concentrations and the relationship to vitamin D, immune status, and inflammation in HIV-infected children and young adults |
| Q39813500 | Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV. |
| Q36952291 | Metabolic complications and treatment of perinatally HIV-infected children and adolescents |
| Q37651634 | Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE. |
| Q36789908 | Physiologic frailty and fragility fracture in HIV-infected male veterans |
| Q40563423 | Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study |
| Q39019753 | Prevalence of vitamin D deficiency in HIV-positive, antiretroviral treatment-naïve patients in a single centre study |
| Q42229887 | Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons |
| Q38836871 | Protecting bone in long-term HIV positive patients receiving antiretrovirals |
| Q34168353 | Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal |
| Q64269479 | Relationship Between Vertebral Fractures, Bone Mineral Density, and Osteometabolic Profile in HIV and Hepatitis B and C-Infected Patients Treated With ART |
| Q37029416 | Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth |
| Q38210581 | Role of vitamin D in acquired immune and autoimmune diseases |
| Q36361380 | Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection |
| Q36634960 | Serum 25-hydroxyvitamin d levels and C-reactive protein in persons with human immunodeficiency virus infection |
| Q92128503 | Serum Vitamin D is Differentially Associated with Socioemotional Adjustment in Early School-Aged Ugandan Children According to Perinatal HIV Status and In Utero/Peripartum Antiretroviral Exposure History |
| Q37111446 | Short communication: High prevalence of vitamin D deficiency in HIV-infected and HIV-uninfected pregnant women |
| Q34404878 | Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers |
| Q35717568 | Success of Standard Dose Vitamin D Supplementation in Treated Human Immunodeficiency Virus Infection |
| Q57143538 | The Hidden Burden of Fractures in People Living With HIV |
| Q37838799 | The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations |
| Q59804870 | The impact of vitamin D supplementation on musculoskeletal health outcomes in children, adolescents, and young adults living with HIV: A systematic review |
| Q37112531 | The relationship between vitamin D status and HIV-related complications in HIV-infected children and young adults |
| Q38005045 | Therapeutic options for low bone mineral density in HIV-infected subjects |
| Q36781481 | Unresolved antiretroviral treatment management issues in HIV-infected children |
| Q93153429 | VDR polymorphisms influence immunological response in HIV-1+ individuals undergoing antiretroviral therapy |
| Q37267250 | Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. |
| Q40517679 | Vitamin D Deficiency and Metabolism in HIV-Infected and HIV-Uninfected Men in the Multicenter AIDS Cohort Study |
| Q40519915 | Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder |
| Q36170370 | Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial |
| Q34328579 | Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral therapy |
| Q36816930 | Vitamin D and bone loss in HIV |
| Q34016783 | Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals |
| Q36200366 | Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States |
| Q35019046 | Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women |
| Q36884537 | Vitamin D in HIV-Infected Patients |
| Q33615509 | Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV |
| Q37492503 | Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals |
| Q37504465 | Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial |
| Q33603196 | Vitamin D, bone, and HIV infection. |
| Q28483914 | Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study |
Search more.